Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

Learn more about:
Related Clinical Trial
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC Feasibility of [11C]Acetate-Positron Emission Tomography (PET) in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex Lymphangioleiomyomatosis, a Study on Cathepsin K Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy KidneYou – Innovative Digital Therapy Gait in Rare Diseases Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Doxycycline In Lymphangioleiomyomatosis (LAM) Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women Turmeric as Treatment in Epilepsy Study of the Disease Process of Lymphangioleiomyomatosis RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM The Effectiveness and Safety of Vagus Nerve Stimulation for TRE The Effectiveness and Safety of Resective Epilepsy Surgery for TRE Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Safety of Simvastatin in LAM and TSC Studies of Autistic Patients: Gene Networks and Clinical Subtypes Topical Rapamycin to Erase Angiofibromas in TSC Rapalogues for Autism Phenotype in TSC: A Feasibility Study A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Everolimus for Cancer With TSC1 or TSC2 Mutation Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex The Cognitive Variability in NF1 and TSC Monozygotic Twins Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex JASPER Early Intervention for Tuberous Sclerosis Studies in Patients With Tuberous Sclerosis Complex Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom) Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Natural History Study: Renal Manifestations Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Study of Skin Tumors in Tuberous Sclerosis

Brief Title

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

Official Title

Randomized Double-Blind Phase 2 Trial Of RAD001 For Neurocognition In Individuals With Tuberous Sclerosis Complex

Brief Summary

      Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures,
      mental retardation and autism, and exhibiting a high variability in clinical findings both
      among and within families. Investigators are doing research in order to identify possible
      neurocognitive benefits from treatment with RAD001 or placebo for a six month period. There
      may also be potential for improvements in seizure frequency, sleep and autistic behaviors. We
      hope this trial will lead to a better understanding of TSC and to new forms of treatment, to
      benefit children and adults with TSC in the future.

      Individuals diagnosed with TSC will be asked to participate in this study if they are between
      the ages of 6 and 21 years of age and have an IQ of greater than or equal to 60. Both males
      and females will be asked to participate. Additionally, to be eligible for study
      participation, individuals must have been on the same seizure medication(s), if applicable,
      for at least 6 months. Individuals must also be able to participate in neuropsychological
      testing and meet certain medical criteria. They will need to sign an informed consent. If
      enrolled in the study, participants will have a number of screening tests to help determine
      if they are eligible for participation in the clinical trial. If eligible for the treatment
      phase of the trial, they will be asked to take either the study drug or a placebo (pill with
      no medicine), which is determined by chance.

      The study involves about 9 visits, 3 of which can be done locally, over a six month period,
      as well as follow-up calls with our research nurse. Study visits will vary in length.
      Screening, three month and six month visits may last up to 8 hours, while all other visits
      will be less than 2 hours. The study visits include blood draws, laboratory tests and
      neuropsychological assessments. There is no fee to participate in this study. The study drug
      will be provided at no charge during the study.

      After all study data has been analyzed, families will be informed of the overall results.
      Treatment on this study may or may not improve a child's learning skills (neurocognition).
      Future patients may benefit from what is learned.

Detailed Description

      This is a signal-seeking Phase II randomized, placebo-controlled trial of RAD001 in children
      and young adults with TSC with neurocognition as the primary outcome and autism spectrum
      disorder as a secondary outcome.

      Specific Aims /Objectives Primary objective

        -  To evaluate the efficacy of RAD001 on neurocognition in patients with TSC compared to
           placebo as measured by well-validated, standardized, direct and indirect neurocognitive

        -  To evaluate the safety of RAD001 compared with placebo in patients with TSC focusing on
           NCI CTCAE Grade 3 and 4 adverse events, serious adverse events, and Grade 3 and 4
           laboratory toxicities.

      Secondary objectives

        -  Comparison of absolute change from baseline in frequency of epileptiform events as
           recorded on seizure diaries between patients taking RAD001 vs. placebo

        -  Comparison of sleep disturbances between patients taking RAD001 vs. placebo, measured by
           the Pediatric Sleep Questionnaire (PSQ) and sleep logs

        -  Comparison of autism spectrum disorders features between patients taking RAD001 vs.
           placebo, measured by ADOS and SRS

        -  Comparison of academic skills between patients taking RAD001 vs. placebo, measured by

        -  Comparison of behavioral problems between patients taking RAD001 vs placebo, measured by
           behavioral rating scales (BRIEF, BASC, SDQ, CHQ and SRS)

Study Phase

Phase 2

Study Type


Primary Outcome

Evaluation of the Safety of RAD001 on Neurocognition in Patients With TSC Compared With Placebo in Patients With TSC.

Secondary Outcome

 Comparison of Absolute Change From Baseline in Frequency of Epileptiform Events Between Patients Taking RAD001 vs. Placebo


Tuberous Sclerosis Complex



Study Arms / Comparison Groups

Description:  RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 2011

Completion Date

December 2014

Primary Completion Date

December 2014

Eligibility Criteria

        Inclusion criteria:

          1. Male or female patients ages 6 to 21 years of age.

          2. IQ ≥60.

          3. Ability to participate in direct neuropsychological and developmental testing.

          4. English as primary language.

          5. Diagnosis of tuberous sclerosis complex confirmed by genetic testing and/or clinically
             definite diagnosis of tuberous sclerosis complex according to the modified Gomez
             criteria and an IQ>60.

          6. Stable anti-epileptic drugs (no changes in medications except dose for >6 months).

          7. Adequate renal function. The GFR would be greater than 50 ml/min.m2 as determined by
             the Schwartz Formula for children and MDRD for adults:


          8. If female and of child bearing potential, documentation of negative pregnancy test
             prior to enrollment. Sexually active pre-menopausal female patients (and female
             partners of male patients) must use adequate contraceptive measures, excluding
             estrogen containing contraceptives, while on study. Abstinence will be considered an
             adequate contraceptive measure.

          9. INR ≤1.5 (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin
             or on a stable dose of LMW heparin for >2 weeks at time of randomization.)

         10. Adequate liver function as shown by:

               -  serum bilirubin ≤ 1.5 x ULN

               -  ALT and AST ≤ 2.5x ULN (≤ 5x ULN in patients with liver metastases)

         11. Written informed consent according to local guidelines.

        Exclusion criteria:

          1. Change of one or more antiepileptic medication in the past 6 months.

          2. Prior exposure to the systemic use of an mTOR inhibitor.

          3. Exposure to any investigational agent in the 30 days prior to randomization.

          4. Neurosurgery within 6 months.

          5. Known impaired lung function (e.g.FEV1 or DLCO <70% of predicted), if not resolved or
             if resolved within past 24 months.

          6. Significant hematological or hepatic abnormality (i.e. transaminase levels > 2.5 x ULN
             or serum bilirubin > 1.5 x ULN, hemoglobin < 9 g/dL, platelets < 80,000/ mm3, absolute
             neutrophil count < 1,000/mm3).

          7. Serum creatinine > 1.5 x ULN.

          8. Uncontrolled hyperlipidemia: Fasting serum cholesterol > 300 mg/dL OR > 7.75 mmol/L
             AND Fasting triglycerides > 2.5 x ULN.

          9. Uncontrolled diabetes mellitus as defined by fasting serum glucose > 1.5 x ULN.

         10. Patients with bleeding diathesis or on oral anti-vitamin K medication (except low dose

         11. Patients with known history of HIV seropositivity.

         12. Pregnancy or breast feeding.

         13. Active infection at date of randomization.

         14. Prior history of organ transplant.

         15. Recent surgery (involving entry into a body cavity or requiring sutures) within the 4
             weeks prior to randomization.

         16. Inability to attend scheduled clinic visits.

         17. History of malignancy in the past two years, other than squamous or basal cell skin

         18. Patients should not receive immunization with attenuated live vaccines within one
             month of study entry or during study period. Close contact with those who have
             received attenuated live vaccines should be avoided during treatment with everolimus.
             Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral
             polio, BCG, yellow fever, varicella and TY21a typhoid vaccines.

         19. Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).

             Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be
             done at screening for all patients. HBV DNA and HCV RNA PCR testing are required at
             screening for all patients with a positive medical history based on risk factors
             and/or confirmation of prior HBV/HCV infection.

         20. Patients receiving chronic, systemic treatment with corticosteroids or another
             immunosuppressive agent. Topical or inhaled corticosteroids are allowed.

         21. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study such as:

               -  symptomatic congestive heart failure of New York heart Association Class III or

               -  unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction within 6 months of start of study drug, serious uncontrolled cardiac
                  arrhythmia or any other clinically significant cardiac disease

         22. Patients who have received an IQ score under 60 in the six months prior to the study
             screening visit will be deemed ineligible.




6 Years - 21 Years

Accepts Healthy Volunteers



Mustafa Sahin, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Mustafa Sahin


 Tuberous Sclerosis Alliance

Study Sponsor

Mustafa Sahin, MD, PhD, Principal Investigator, Boston Children's Hospital

Verification Date

January 2018